Advanced analytics. Intelligent insights.

IXICO plc (AIM: IXI), is a leading neuroimaging Contract Research Organization (CRO), delivering advanced Ai analytical insights in neuroscience to the global clinical trials market. Established in 2004, listed as a public company in 2013, IXICO has firmly established itself as a trusted partner to the global life sciences industry, supporting the development of new therapies for neurological conditions such as Alzheimer’s, Parkinson’s, Huntington’s Disease and Multiple Sclerosis.

With our focus on neuroscience, our purpose is to advance human health by turning data into clinically valuable insights; helping our clients reduce clinical development risk and improve return on investment from their clinical development programmes. We achieve this by combining Ai machine learning imaging biomarker analysis, together with centralised neuroimaging CRO services to provide an integrated service covering every stage of clinical development through to post-marketing surveillance. We are committed to invest in continuously enhancing our validated and peer reviewed disease optimised machine learning Ai analytics services and our infrastructure and technology to support our ambitious growth strategy. Our people are empowered to enable us to achieve   our company goals and their own personal development through the “4A” values at the heart of our culture: Aspiration, Ability, Agility and Accountability.